Cancer Control and Prevention Protocols
Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer
Eligible for screening study DCP 001
NRG CC004 is permanently closed to accrual, due to drug expiration dates. All patients registered to Step 1 registration by 5pm ET, Friday, April 24, 2020 will be permitted to proceed to the randomization step (Step 2).
This protocol has additional regulatory requirements to be completed prior to registering any patients at your site. Please contact Amber Boerner at 406-969-6067 or firstname.lastname@example.org for additional information.